Astrana Health, Inc. (ASTH): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Astrana Health, Inc. (ASTH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2614755d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 ASTRANA HEALTH, INC. AMENDED AND RESTATED 2024 EQUITY INCENTIVE PLAN 1. Establishment, Purpose, Duration . (a) Establishment; Amendment and Restatement . Astrana Health, Inc. (the “ Company ”) originally established the A
How this was made
The 30-second read
Why it matters
The most actionable element for markets is whether the restated plan changes the size/terms of the equity pool and how it aligns with director/officer compensation; the provided excerpt does not include quantified dilution or specific new grants.
Market read
Primarily governance/compensation disclosure; potential secondary effects via dilution/retention expectations, but no direct financial guidance or operational catalyst is disclosed in the excerpt.
What to watch
Traders may want to check the full 8-K for the actual share reserve/maximum award limits and any director/officer appointment details, which can be more market-relevant than the boilerplate plan definitions.
Background
The filing is an SEC Form 8-K (Item 5.02/5.07) that includes an exhibit describing an amended and restated 2024 Equity Incentive Plan, with a new effective date of March 25, 2026, contingent on stockholder approval at the 2026 Annual Meeting.
Ticker impact
Astrana Health filed an 8-K detailing an amended and restated 2024 equity incentive plan effective March 25, 2026, subject to stockholder approval.
Likely limited near-term price impact unless investors focus on plan terms/dilution or anticipate material equity grants tied to the new plan.
The disclosure is primarily about plan mechanics (amendment/restatement, definitions, duration) rather than new operating guidance, contracts, or enforcement outcomes.
Market effects
Minimal—equity incentive plan restatements are common across healthcare services/managed care and generally do not reset sector fundamentals.
None indicated.
None indicated.
Counterpoint
If the amended plan increases share pool capacity or changes award mix (not quantified in the excerpt), it could be modestly dilutive and weigh on valuation multiples despite the neutral framing.
Key entities
- issuerAstrana Health, Inc.
Company filing the 8-K and the equity incentive plan amendment/restatement.
- compensation_plan2024 Equity Incentive Plan (amended/restated)
Equity compensation framework for directors, officers, consultants, and employees; restated effective March 25, 2026 subject to stockholder approval.
